NEW YORK, June 5, 2017 /PRNewswire/ --
Featured on DailyStockTracker.com this morning are the four stocks withinthe Biotech space: 22nd Century Group Inc. (NYSE MKT: XXII), Calithera Biosciences Inc. (NASDAQ: CALA), Five Prime Therapeutics Inc. (NASDAQ: FPRX), and Advaxis Inc. (NASDAQ: ADXS). According to a Zacks report, a key concern for the Biotech
Clarence, New York headquartered 22nd Century Group Inc.'s shares rose 2.19%, finishing last Friday's session at $1.40. A total volume of 336,092 shares was traded. Over the last month and the previous three months, the stock has advanced 2.94% and 50.54%, respectively. Furthermore, the Company's shares have gained 28.44% since the start of this year. The stock is trading above its 50-day and 200-day moving averages by 6.06% and 23.26%, respectively. Additionally, shares of 22nd Century, which provides technology that allows for the level of nicotine and other nicotinic alkaloids in tobacco plants to be decreased or increased through genetic engineering and plant breeding, have a Relative Strength Index (RSI) of 56.02.
On June 01st, 2017, the Company announced that its wholly owned subsidiary, Goodrich Tobacco Company, received a new purchase order for agencies of the US federal government for 2.4 million of the Company's proprietary SPECTRUM research cigarettes. SPECTRUM brand cigarettes are important tools in clinical research for investigating the impact of reduced nicotine levels for cigarette addictiveness and cessation success. Your complete research report on XXII can be retrieved for free at: http://dailystocktracker.com/registration/?symbol=XXII
On Friday, shares in South San Francisco, California headquartered Calithera Biosciences Inc. ended the session 2.48% lower at $15.70. The stock recorded a trading volume of 373,724 shares. The Company's shares have gained 42.08% in the last month, 26.61% in the previous three months, and 383.08% on an YTD basis. The stock is trading above its 50-day and 200-day moving averages by 27.06% and 129.71%, respectively. Moreover, shares of Calithera Biosciences, which focuses on discovering and developing small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the US, have an RSI of 60.00.
On May 10th, 2017, Calithera Biosciences and Bristol-Myers Squibb announced that they have expanded their existing collaboration to evaluate the latter's Opdivo in combination with Calithera's CB-839 in patients with non-small cell lung cancer and melanoma. CB-839 is an investigational, orally administered, glutaminase inhibitor currently in Phase-1/2 clinical studies. A free report on CALA is just a click away at: http://dailystocktracker.com/registration/?symbol=CALA
Five Prime Therapeutics
South San Francisco, California headquartered Five Prime Therapeutics Inc.'s stock climbed 1.76%, to close the day at $29.52 with a total trading volume of 329,203 shares. The stock is trading 8.83% below their 50-day moving average. Shares of the Company, which focuses on the discovery and development of immuno-oncology protein therapeutics in the US, have an RSI of 43.57.
On May 15th, 2017, Five Prime Therapeutics announced the appointment of Garry Nicholson to its board of directors. Mr. Nicholson served as XTuit Pharma's President and CEO from September 2015 to October 2016. From May 2008 to March 2015, he served at Pfizer Inc. as President, Pfizer Oncology. Sign up for your complimentary research report on FPRX at: http://dailystocktracker.com/registration/?symbol=FPRX
Shares in Princeton, New Jersey-based Advaxis Inc. recorded a trading volume of 493,934 shares. The stock ended at $8.07, slightly down 0.37% from the last trading session. The Company's shares have gained 12.71% on an YTD basis. The stock is trading below its 50-day moving average by 1.41%. Furthermore, shares of Advaxis, which focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the US, have an RSI of 45.83.
On May 30th, 2017, Advaxis and Bristol-Myers Squibb (BMY) announced a clinical development collaboration to evaluate ADXS-DUAL, an investigational immunotherapy targeting HPV-associated cancers, and BMY's PD-1 immune checkpoint inhibitor, Opdivo (nivolumab), as a potential combination treatment option for women with metastatic cervical cancer. Under the terms of the agreement, each party will bear its own internal costs, and provide its immunotherapy agents. Register for free on DailyStockTracker.com and download the latest research report on ADXS at: http://dailystocktracker.com/registration/?symbol=ADXS
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: email@example.com Phone number: (207)-331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Chelmsford Park SA
Subscribe to our Free Newsletters!
Pterygium or Surfer's eye is described as a proliferative disorder of the ocular surface possibly ...
Ecchymosis is a flat, discolored patch of skin that occurs when there is bleeding underneath; it is ...
Age related macular degeneration is a disease of the elderly, wherein the macula or the central ...View All